KALA BIO
KALA
54 hedge funds and large institutions have $328M invested in KALA BIO in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 14 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
0% more funds holding
Funds holding: 54 → 54 (0)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
7% less capital invested
Capital invested by funds: $353M → $328M (-$25.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.99M |
| 2 |
Neuberger Berman Group
New York
|
+$4.03M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$2.29M |
| 4 |
EU
Emory University
Atlanta,
Georgia
|
+$1.87M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$4.57M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.15M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.32M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.37M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.35M |
KALA Hedge Fund Activity: Q4 2017 in Review
54 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2017, worth a combined $328M — down 7.3% from $353M a quarter earlier.
Fund positioning in KALA was balanced in Q4 2017: 14 funds opened new positions, 14 closed out, 20 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $5.99M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $4.57M sold.
- 54 institutional investors held KALA BIO (KALA) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $328M of KALA BIO stock for Q4 2017, down 7.3% quarter-over-quarter.
- 14 funds opened new KALA BIO positions in Q4 2017 and 14 closed out, a net change of 0 holders.
- The largest KALA BIO buyer in Q4 2017 was BlackRock, an estimated $5.99M added.
- The largest KALA BIO seller in Q4 2017 was Laurion Capital Management, an estimated $4.57M sold.
Based on aggregated 13F filings for Q4 2017.